The Molecular Basis of Rectal Cancer

Abstract

The majority of rectal carcinomas are sporadic in nature, and relevant testing for driver mutations to guide therapy is important. A thorough family history is necessary and helpful in elucidating a potential hereditary predilection for a patient's carcinoma. The adequate diagnosis of a heritable tendency toward colorectal carcinoma alters the management of a patient disease and permits the implementation of various surveillance algorithms as preventive measures.

Keywords

colorectal cancer - molecular testing - hereditary cancer - adenoma-carcinoma sequence

• References

• 1 Bhalla A, Zulfiqar M, Weindel M, Shidham VB. Molecular diagnostics in colorectal carcinoma. Clin Lab Med 2013; 33 (4) 835-859
• 2 Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383 (9927) 1490-1502
• 3 Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138 (6) 2073-2087.e3
• 4 Kircher SM, Mohindra N, Nimeiri H “ http://www.ncbi.nlm.nih.gov/pubmed/25410095 ” Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer. Oncologist 2015; 20 (1) 14-18
• 5 Wendy DeRoock, Bart Claes, David Bernasconi , et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11 (8) 753-762
• 6 Wendy DeRoock, Veerle DeVriendt, Nicola Normanno, Fortunato Ciardiello, Sabine Tejpar. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12 (6) 594-603
• 7 Tanja K Froehlich, Ursula Amstutz, Stefan Aebi, Markus Joerger, Carlo R. Largiadér. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2014; 136 (3) 730-739
• 8 Inoue K, Sonobe M, Kawamura Y , et al. Polymorphisms of the UDP-glucuronosyl transferase 1A Genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. Tohoku J Exp Med 2013; 229: 107-114
• 9 Buecher B, Cacheux W, Rouleau E , et al. Role of microsatellite instability in the management of colorectal cancers. Dig Liver Dis 2013; 45: 441-449
• 10 Chargelaigue A. Des Polypes du Rectum. Thesis Paris; 1859
• 11 Lucci-Cordisco E, Risio M, Venesio T, Genuardi M. The growing complexity of the intestinal polyposis syndromes. Am J Med Genet A 2013; 161A (11) 2777-2787
• 12 Sieber OM, Tomlinson IP, Lamlum H. The adenomatous polyposis coli (APC) tumour suppressor—genetics, function and disease. Mol Med Today 2000; 6 (12) 462-469
• 13 Lindor NM. Recognition of genetic syndromes in families with suspected hereditary colon cancer syndromes. Clin Gastroenterol Hepatol 2004; 2 (5) 366-375
• 14 Kerr SE, Thomas CB, Thibodeau SN, Ferber MJ, Halling KC. APC germline mutations in individuals being evaluated for familial adenomatous polyposis: a review of the Mayo Clinic experience with 1591 consecutive tests. J Mol Diagn 2013; 15 (1) 31-43
• 15 Church J, Burke C, McGannon E, Pastean O, Clark B. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 2003; 46 (9) 1175-1181
• 16 Vasen HF, van Duijvendijk P, Buskens E , et al. Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: a Dutch-Scandinavian collaborative study including 659 patients. Gut 2001; 49 (2) 231-235
• 17 Nugent KP, Phillips RK. Rectal cancer risk in older patients with familial adenomatous polyposis and an ileorectal anastomosis: a cause for concern. Br J Surg 1992; 79 (11) 1204-1206
• 18 Bertario L, Presciuttini S, Sala P, Rossetti C, Pietroiusti M ; Italian Registry of Familial Polyposis Writing Committee. Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Semin Surg Oncol 1994; 10 (3) 225-234
• 19 De Cosse JJ, Bülow S, Neale K , et al; The Leeds Castle Polyposis Group. Rectal cancer risk in patients treated for familial adenomatous polyposis. Br J Surg 1992; 79 (12) 1372-1375
• 20 Tuckson W, Lavery I, Fazio V, Oakley J, Church J, Milsom J. Manometric and functional comparison of ileal pouch anal anastomosis with and without anal manipulation. Am J Surg 1991; 161 (1) 90-95 , discussion 95–96
• 21 Church JM, Oakley JR, Wu JS. Pouch polyposis after ileal pouch-anal anastomosis for familial adenomatous polyposis: report of a case. Dis Colon Rectum 1996; 39 (5) 584-586
• 22 Remzi FH, Church JM, Bast J , et al. Mucosectomy vs. stapled ileal pouch-anal anastomosis in patients with familial adenomatous polyposis: functional outcome and neoplasia control. Dis Colon Rectum 2001; 44 (11) 1590-1596
• 23 van Duijvendijk P, Vasen HF, Bertario L , et al. Cumulative risk of developing polyps or malignancy at the ileal pouch-anal anastomosis in patients with familial adenomatous polyposis. J Gastrointest Surg 1999; 3 (3) 325-330
• 24 Ziv Y, Fazio VW, Sirimarco MT, Lavery IC, Goldblum JR, Petras RE. Incidence, risk factors, and treatment of dysplasia in the anal transitional zone after ileal pouch-anal anastomosis. Dis Colon Rectum 1994; 37 (12) 1281-1285
• 25 Remzi FH, Fazio VW, Delaney CP , et al. Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of prospective evaluation after a minimum of ten years. Dis Colon Rectum 2003; 46 (1) 6-13
• 26 Ooi BS, Remzi FH, Gramlich T, Church JM, Preen M, Fazio VW. Anal transitional zone cancer after restorative proctocolectomy and ileoanal anastomosis in familial adenomatous polyposis: report of two cases. Dis Colon Rectum 2003; 46 (10) 1418-1423 , discussion 1422–1423
• 27 Vrouenraets BC, Van Duijvendijk P, Bemelman WA, Offerhaus GJ, Slors JF. Adenocarcinoma in the anal canal after ileal pouch-anal anastomosis for familial adenomatous polyposis using a double-stapled technique: report of two cases. Dis Colon Rectum 2004; 47 (4) 530-534
• 28 O'Connell PR, Williams NS. Mucosectomy in restorative proctocolectomy. Br J Surg 1991; 78 (2) 129-130
• 29 Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009; 76 (1) 1-18
• 30 Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010; 138 (6) 2044-2058
• 31 Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001; 91 (12) 2417-2422
• 32 Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158 (2) 527-535
• 33 Jass JR. Pathology of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci 2000; 910: 62-73, discussion 73–74
• 34 Fitzgibbons Jr RJ, Lynch HT, Salerno GM. Hereditary colon cancer syndromes. Surg Annu 1991; 23 (Pt 2) 111-132
• 35 Parry S, Win AK, Parry B , et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60 (7) 950-957
• 36 Natarajan N, Watson P, Silva-Lopez E, Lynch HT. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum 2010; 53 (1) 77-82
• 37 You YN, Chua HK, Nelson H, Hassan I, Barnes SA, Harrington J. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life. Dis Colon Rectum 2008; 51 (7) 1036-1043
• 38 Cirillo L, Urso ED, Parrinello G , et al. High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria. Ann Surg 2013; 257 (5) 900-904
• 39 Borras E, Taggart MW, Lynch PM, Vilar E. Establishing a diagnostic road map for MUTYH-associated polyposis. Clin Cancer Res 2014; 20 (5) 1061-1063
• 40 Morak M, Heidenreich B, Keller G , et al. Biallelic MUTYH mutations can mimic Lynch syndrome. Eur J Hum Genet 2014; 22 (11) 1334-1337
• 41 Guarinos C, Sánchez-Fortún C, Rodríguez-Soler M , et al. Clinical subtypes and molecular characteristics of serrated polyposis syndrome. Clin Gastroenterol Hepatol 2013; 11 (6) 705-711 , quiz e46
• 42 Landon M, Ceulemans S, Saraiya DS , et al. Analysis of current testing practices for biallelic MUTYH mutations in MUTYH-associated polyposis. Clin Genet 2014; ;•••: 10.1111/cge.12375
• 43 Castillejo A, Vargas G, Castillejo MI , et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. Eur J Cancer 2014; 50 (13) 2241-2250
• 44 Brosens LA, Langeveld D, van Hattem WA, Giardiello FM, Offerhaus GJ. Juvenile polyposis syndrome. World J Gastroenterol 2011; 17 (44) 4839-4844
• 45 Latchford AR, Neale K, Phillips RK, Clark SK. Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome. Dis Colon Rectum 2012; 55 (10) 1038-1043
• 46 Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep 2012; 14 (5) 428-438
• 47 Jelsig AM, Qvist N, Brusgaard K, Nielsen CB, Hansen TP, Ousager LB. Hamartomatous polyposis syndromes: a review. Orphanet J Rare Dis 2014; 9: 101
• 48 Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105 (21) 1607-1616
• 49 Shuch B, Ricketts CJ, Vocke CD , et al. Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol 2013; 190 (6) 1990-1998
• 50 Jaeger E, Leedham S, Lewis A , et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet 2012; 44 (6) 699-703
• 51 Whitelaw SC, Murday VA, Tomlinson IP , et al. Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology 1997; 112 (2) 327-334
• 52 Gala MK, Mizukami Y, Le LP , et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology 2014; 146 (2) 520-529
• 53 Palles C, Cazier JB, Howarth KM , et al; CORGI Consortium; WGS500 Consortium. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013; 45 (2) 136-144